Clinical Trial Update: A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study of biweekly pemetrexed in combination with gemcitabine for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED